Medically reviewed by Christopher Lee, MD Key Takeaways Cardiomyopathy is a disease that affects the heart muscle, making it weak or stiff.Medication, surgery, and lifestyle changes can help improve ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III ...

StemRIM Inc. has commenced a Phase 2 clinical trial for its regenerative medicine product, Redasemtide, targeting ischemic cardiomyopathy at Osaka University Hospital. This trial aims to evaluate the ...

The Defibrillators in Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial was conducted to evaluate the prophylactic implantation of an ICD to prevent sudden death in patients with ...

MYQORZO was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms, and by the China National Medical ...

Researchers from Queen Mary University of London have found that a medication originally developed for glycemic control can reverse serious heart damage—not by controlling blood sugar as originally ...

The study tests mavacamten, an oral heart drug designed to improve how the heart muscle relaxes and pumps in hypertrophic cardiomyopathy. The treatment aims to cut symptoms like shortness of breath ...

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of ...

The number of patients diagnosed with cardiomyopathy has increased substantially over the past two decades. This is the finding of a new study from Uppsala University that mapped all cases of ...